https://www.pharmaceutical-technology.com/data-insights/likelihood-of-approval-malignant-fibrous-histiocytoma-of-soft-tissue/
Malignant Fibrous Histiocytoma of Soft Tissue disease is an indication for drug development with over 10 pipeline drugs currently active according to...
fibrous histiocytomasoft tissuemalignantdrugslikelihood
https://www.pharmaceutical-technology.com/data-insights/ava-6000-avacta-life-sciences-malignant-fibrous-histiocytoma-likelihood-of-approval/
AVA-6000 is under clinical development by Avacta Life Sciences and currently in Phase I for Malignant Fibrous Histiocytoma.
life sciencesfibrous histiocytomaavamalignant
https://pubmed.ncbi.nlm.nih.gov/1650235/
Clinical, light microscopic and immunohistochemical features of four cases of primary malignant fibrous histiocytoma (MFH) of the breast are presented....
fibrous histiocytomaprimarymalignantbreastreport
https://www.pharmaceutical-technology.com/data-insights/malignant-fibrous-histiocytoma-of-soft-tissue-drugs-in-development/
GlobalData tracks 11 drugs in development for Malignant Fibrous Histiocytoma of Soft Tissue by ten companies/universities/institutes. The top development phase...
fibrous histiocytomasoft tissuemalignantdrugsdevelopment